scholarly journals Family history of cancer in children with acute leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma: The ESCALE study (SFCE)

2007 ◽  
Vol 121 (1) ◽  
pp. 119-126 ◽  
Author(s):  
Jérémie Rudant ◽  
Florence Menegaux ◽  
Guy Leverger ◽  
André Baruchel ◽  
Brigitte Nelken ◽  
...  
Keyword(s):  
Family History ◽  
Acute Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Family History Of Cancer ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
History Of ◽  
Cancer In Children ◽  
History Of Cancer

scholarly journals Family history of haematopoietic malignancies and non-Hodgkin's lymphoma risk in the California Teachers Study

2009 ◽  
Vol 100 (3) ◽  
pp. 524-526 ◽  
Author(s):  
Y Lu ◽  
J Sullivan-Halley ◽  
W Cozen ◽  
E T Chang ◽  
K Henderson ◽  
...  
Keyword(s):  
Family History ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
History Of ◽  
Lymphoma Risk

scholarly journals Non-Hodgkin's Lymphoma and Family History of Hematologic Malignancy

2006 ◽  
Vol 165 (2) ◽  
pp. 126-133 ◽  
Author(s):  
F. Mensah ◽  
E. Willett ◽  
P Ansell ◽  
P. Adamson ◽  
E Roman
Keyword(s):  
Family History ◽  
Hodgkin’S Lymphoma ◽  
Hematologic Malignancy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
History Of

scholarly journals Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma

2008 ◽  
Vol 98 (5) ◽  
pp. 1001-1005 ◽  
Author(s):  
A Andersson ◽  
G Enblad ◽  
B Tavelin ◽  
M Björkholm ◽  
J Linderoth ◽  
...  
Keyword(s):  
Risk Factor ◽  
Family History ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Second Malignancies ◽  
Family History Of Cancer ◽  
History Of ◽  
History Of Cancer

scholarly journals Family History of Hemolymphopoietic and Other Cancers and Risk of Non-Hodgkin's Lymphoma

2006 ◽  
Vol 15 (2) ◽  
pp. 245-250 ◽  
Author(s):  
Eva Negri ◽  
Renato Talamini ◽  
Maurizio Montella ◽  
Luigino Dal Maso ◽  
Anna Crispo ◽  
...  
Keyword(s):  
Family History ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
History Of

scholarly journals Risk factors for non-Hodgkin's lymphoma according to family history of haematolymphoproliferative malignancies

2001 ◽  
Vol 30 (4) ◽  
pp. 818-824 ◽  
Author(s):  
Kangmin Zhu ◽  
Robert S Levine ◽  
Edward A Brann ◽  
Yuan Gu ◽  
Lee S Caplan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Family History ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
History Of

scholarly journals The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation

Blood ◽  
1990 ◽  
Vol 75 (4) ◽  
pp. 831-838 ◽  
Author(s):  
GL Phillips ◽  
JW Fay ◽  
RH Herzig ◽  
HM Lazarus ◽  
SN Wolff ◽  
...  
Keyword(s):  
Marrow Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Disease Status ◽  
Hodgkin's Lymphoma ◽  
Prior History ◽  
Resistant Disease ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Cause Of Failure ◽  
History Of

Abstract Intensive chemoradiotherapy, with or without additional local radiotherapy, and unpurged autologous marrow transplantation was given to 68 patients with progressive non-Hodgkin's lymphoma. Responses were attained in 44 patients (65%, 95% confidence intervals [CI], 52% to 76%), including 37 who achieved complete responses. Fifteen patients (22%, 95% C.I. 13% to 34%) remain free of disease (including 11 continuously) at a median of 5.3 (range 3.1 to 9.1) years later. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and the absence of a history of prior radiotherapy (P = .02, chi 2 test) were associated with achievement of complete plus partial responses. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and less resistant disease status at transplantation (P = .04, chi 2 test) were significant when calculations were limited to complete responses. Karnofsky scores were also associated with the probability of freedom from progression (P = .02, log-rank) for responding patients. Also, Karnofsky scores and the absence of prior radiotherapy (P less than .01 and P = .01, respectively, log-rank) were associated with improved survival. Progressive lymphoma was the chief cause of failure; progression usually occurred less than 6 months after transplantation, most often at the sites of active disease before the transplant. However, five patients (including four with high-grade non-Hodgkin's lymphoma) suffered hematogenous patterns of relapse; four of these five patients had no prior history of marrow involvement. Other causes of mortality included interstitial pneumonitis, sepsis, hemorrhage and renal failure. Intensive chemoradiotherapy and autologous marrow transplantation produces durable remissions in some patients with progressive non-Hodgkin's lymphoma. Since such therapy is more effective when given to patients with signs of less advanced disease, earlier treatment would be the simplest way to produce improved results. However, improved conditioning regimens will also be needed, and measures to reduce occult lymphoma stem cell contamination with the autograft may also be required to increase the likelihood of cure in some patients.

Risk Factors for Venous Thromboembolism (VTE) among Patients with Active Hematological Cancer: A Population-Based Case-Control Study.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1642-1642
Author(s):  
Aneel A. Ashrani ◽  
John A. Heit ◽  
Jeffrey A. Schmoll ◽  
Sara A. Farmer ◽  
Tanya M. Petterson ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Leukemia ◽  
Cancer Patients ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Cancer Type ◽  
Hematological Cancer ◽  
Stage Progression ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Background: Hematological cancer patients are at an increased risk for VTE (RR range = 12–32). However, whether VTE risk among such patients can be further stratified is uncertain. Objective: To test hematological cancer type, stage, stage progression and chemotherapy as potential risk factors for VTE among active hematological cancer patients after controlling for other previously-identified VTE risk factors. Methods: Using the resources of the Rochester Epidemiology Project, Mayo Clinic Master Diagnostic Index and Mayo Clinic Tumor Registry, we identified all Olmsted County, MN residents with active hematological cancer over the 28-year period, 1973–2000. From this prevalence cohort, we identified 86 patients with no prior VTE (controls) who were matched on age and date of hematological cancer diagnosis to 86 hematological cancer patients with incident VTE over the same time frame (cases). For all cases and controls, we reviewed the complete medical records in the community for baseline and hematological cancer-related characteristics. Hematological cancers were re-staged at the dates of the cancer and VTE diagnosis. We tested these characteristics as potential risk factors for VTE in active hematological cancer using conditional logistic regression. Results: In an initial multivariate analysis that included body mass index (BMI), hospitalization, and any infection or central venous catheter placement within 90 days prior to the VTE event, VTE was significantly associated with hospitalization (OR=6.70; p<0.001), and marginally associated with any infection (OR=2.18; p=0.09). After adjusting for the above variables, chemotherapy administered within the preceding 90 days was significantly associated with VTE (OR=4.25; p=0.02), while stage progression was marginally associated (OR=4.79; p=0.10). Compared to all other hematological cancer types, acute leukemia (OR=5.95; p=0.01) and non-Hodgkin’s lymphoma (OR=2.61; p=0.01) were associated with VTE. However, after adjusting for BMI, hospitalization, any infection and central venous catheter, only non-Hodgkin’s lymphoma was independently associated with VTE (OR=3.79, p=0.009), while acute leukemia was not (OR=2.66, p=0.35). Conclusions: Hematological cancer type (in particular, non-Hodgkin’s lymphoma and possibly acute leukemia), recent hospitalization, recent chemotherapy, and possibly stage progression and recent infection, are risk factors for VTE among patients with active hematological cancer.

Sign in / Sign up

Export Citation Format

Share Document